Drug intelligence / Profile preview

IXA-003

Development stage: Unknown
Lead developer: IXALTIS
Modality: Small Molecules
Administration: Oral

Overview

**IXA-003** is a selective **MAO-B inhibitor** developed by **IXALTIS** for urological disorders. It selectively inhibits **monoamine oxidase B (MAO-B)**, an enzyme involved in neurotransmitter metabolism, potentially modulating dopaminergic and serotonergic pathways relevant to lower urinary tract symptoms. The drug has completed **Phase I** studies demonstrating safety and has shown **preclinical proof-of-concept** in urological disease models, with its global R&D status currently at the **preclinical** stage.[1][3]

Targets

MAOB (Monoamine oxidase B)

Beyond the preview

Go deeper on IXA-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IXA-003.

Explore the full profile